Tough on HCC, not on patients
TheraSphere® is a powerfula, well-tolerated Y-90 glass microsphere therapy for transarterial
radioembolization (TARE) in HCC, providing demonstrated patient bene;tsb and rapid administration
set-up, leading to a safe and quicker infusion4.
Tough on HCC
• Two independent studies reported median survival
rates of 17. 2 months in Child-Pugh A hepatocellular
carcinoma (HCC) cirrhotic patients with various tumor
characteristics (N=291, N=108)
• WHO and EASL response rates were 42% and 57%,
• 58% of TheraSphere patients were downstaged3
Easy on patients
• The majority of adverse events were mild to moderate
in severity4 and were manageable or resolved over time2
• No ulcers or pulmonary toxicities were reported in two
large independent studies (N=291, N=108)
• Administered as an outpatient treatment
For more information, visit
References: 1. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report for
long-term outcomes. Gastroenterology. 2010;138: 52-64. 2. Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular
carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52:1741-1749. 3. Le wandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of
transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920-1928. 4. Thera Sphere® [US package insert].
Otta wa, ON: Nordion (Canada) Inc.; 2011.
Nordion, the logo and Science Advancing Health are trademarks of Nordion (Canada) Inc. and are used under license by Nordion Inc.
Targeted Tough is a trademark of Nordion (Canada) Inc. Thera Sphere® is a trademark of Theragenics Corporation used under license by
Nordion (Canada) Inc. All rights reserved. January 2012, Printed in Canada. PCCS 503A
a - Refers to high speci;c activity.
b - Patient bene;ts as indicated by Package Insert: HCC patients with PV T are eligible for treatment, majority of events graded as mild to moderate, treatment usually
performed on an outpatient basis.